QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings

/PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on bi-specific antibodies and other engineered bio-therapeutics for the...

Related Keywords

Shanghai ,China ,United States ,Shenzhen ,Guangdong ,Peking ,Beijing ,Chicago ,Illinois ,Hangzhou ,Zhejiang ,Lin Shen ,Jundu ,Shanxi ,American ,Viva Bio ,Jifang Gong ,American Society Of Clinical Oncology ,University Cancer Hospital ,Department Of Gastrointestinal Oncology ,Qurebio Ltd ,Hengrui Pharmaceuticals ,Shanghai Pudong Kechuang Group ,Prnewswire Qurebio Ltd ,Bocom Industrial Investment Hangzhou Equity Partnership ,Shenzhen Capital Group ,Suzhou Oriza Holdings ,Fbio Ltd ,American Society ,Clinical Oncology ,Annual Meetings ,Peking University Cancer Hospital ,Meeting Abstracts ,Gastrointestinal Oncology ,Developmental Therapeutics ,Chicago Time ,Viva Bio Innovator ,Jundu Investment ,Watson Capital ,Bocom Industrial Investment ,Equity Investment Partnership ,Zhuhai Longmen Capital Management ,Shenzhen Lihe Hongxin Venture ,Three Rivers ,Precision Scientific ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,Trade Show News ,